What to read after Oxford Textbook of Cancer in Children?

The outcome for children with cancer has shown enormous improvement since the first edition of this book was published in 1975. In economically privileged countries, overall survival rates have now reached 80% at five years from diagnosis, and most of these young people will become long term survivors. The Oxford Textbook of Cancer in Children offers state-of-the-art descriptions of the approach needed for the optimal management of children with cancer, and guidance on current treatments available due to the advances made over the past decade. This seventh edition has been thoroughly revised and updated, including brand new chapters on cancer immunotherapy in children, and cancer in adolescents and young adults, plus expanded treatment of tumours of the brain and central nervous system. The book primarily provides clear and up-to-date clinical guidance for use in treatment settings whilst offering a useful background to the biology of individual tumour types and the history of the development of specific treatments. With an international and multi-disciplined authorship comprising of paediatric oncologists, surgeons, radiotherapists, imaging specialists, psychologists, nurses, and many others, the text illustrates how the paediatric oncology community works globally and collaboratively in order to drive forward new therapies, build our knowledge of these diseases, and achieve the common aim of curing childhood cancer. In this new edition, Professors Biondi and Caron have been joined by Professor François Doz, who has a distinguished international reputation, particularly in the treatment of childhood brain tumours and retinoblastoma, as well as early drug development. They have also been joined by Professor Tom Boterberg, a world renowned radio-oncologist for children with cancer. This book will be of value to paediatric oncologists, trainee paediatric oncologists, paediatric haematologists, and other professionals working in paediatric oncology: nurses, AHPs, surgeons, and clinical oncologists.